12 completed, 7 terminated, 3 active not recruiting, 3 unknown. 27 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 27 | Completed 12, Terminated 7, Active not recruiting 3, Unknown 3, Recruiting 2 |
| Phase 2 | 6 | Terminated 4, Completed 1, Unknown 1 |
Follow Nerve Sheath Neoplasms: new trials by email Literature Review of Nerve Sheath Neoplasms trials Research Report on Nerve Sheath Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 177 | 2026-03-31 | 2026-05-27 |
| Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients Steroids therapy, Placebo - Vestibular Schwannoma, Facial Nerve Paralysis | Phase 3 | Recruiting | Beijing Tiantan Hospital | 364 | 2025-10-09 | 2026-10-26 |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 3 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 167 | 2023-06-20 | 2025-03-06 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN) | Phase 3 | Active not recruiting | AstraZeneca | 145 | 2021-11-19 | 2026-11-12 |
| A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NPC-12G gel - Neurofibromatosis | Phase 3 | Terminated | Nobelpharma | 100 | 2020-07-08 | 2022-05-24 |
| Vitamin D3 in Sensory Recovery After Digital NERVe Suture (D3NERV). Cholecalciferol, Placebos - Digital Nerve Injury | Phase 3 | Unknown | University Hospital, Caen | 72 | 2020-01-20 | 2021-08-31 |
| A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment - Low Grade Glioma, Neurofibromatosis Type 1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 165 | 2020-01-15 | 2026-11-12 |
| Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 3 | Terminated | Novartis Pharmaceuticals | 535 | 2018-10-30 | 2023-01-30 |
| Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Acceptance and Commitment Therapy (ACT) - Neurofibromatosis Type 1, Plexiform Neurofibromas | Phase 3 | Completed | National Cancer Institute (NCI) | 66 | 2015-07-07 | 2022-06-14 |
| Effect of Lamotrigine on Cognition in NF1 Lamotrigine, Placebo - Neurofibromatosis Type 1 | Phase 2 / Phase 3 | Terminated | Erasmus Medical Center | 41 | 2014-10-01 | 2020-04-14 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide - Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 140 | 2014-08-12 | 2026-06-17 |
| Stereotactic Radiation in Vestibular Schwannoma stereotactic radiotherapy, stereotactic radiosurgery - Vestibular Schwannoma | Phase 3 | Unknown | Ramathibodi Hospital | 200 | 2011-10-01 | 2011-10-10 |
| Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 133 | 2011-05-01 | 2014-08-08 |
| Efficacy and Safety of Ralfinamide in Patients With Chronic Neuropathic Low Back Pain Ralfinamide - Pain | Phase 3 | Completed | Newron Pharmaceuticals SPA | 411 | 2009-03-20 | 2017-09-15 |
| Corticosteroids in Prevention of Facial Palsy After Cranial Base Surgery methylprednisolone - Facial Palsy | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 313 | 2007-03-01 | 2012-07-10 |
| Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery - Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma | Phase 3 | Completed | Children's Oncology Group | 588 | 2007-02-05 | 2022-04-28 |
| Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors imatinib mesylate - Malignant Peripheral Nerve Sheath Tumors | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 11 | 2006-05-01 | 2012-08-07 |
| First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Erbium-YAG laser vaporization - Cutaneous Neurofibromas | Phase 2 / Phase 3 | Unknown | Medical University of Vienna | 12 | 2006-04-01 | 2011-07-13 |
| Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma radiotherapy - Sarcoma | Phase 3 | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 216 | 2006-03-01 | 2021-03-18 |
Showing 20 of 27. Sign in to see all of them.
Neurofibrosarcoma (11) · Fibrosarcoma (10) · Histiocytoma, Malignant Fibrous (10) · Leiomyosarcoma (10) · Sarcoma (10) · Sarcoma, Synovial (10) · Hemangiosarcoma (9) · Liposarcoma (9) · Hemangiopericytoma, Malignant (6) · Neurofibromatosis 1 (6) · Sarcoma, Alveolar Soft Part (6) · Malignant mesenchymal tumor (5) · Chondrosarcoma, Extraskeletal Myxoid (4) · Neurofibroma, Plexiform (4) · Rhabdomyosarcoma (4)
Neoplasms (27) · Neoplasms by Histologic Type (27) · Neoplasms, Nerve Tissue (27) · Nervous System Diseases (25) · Neurofibroma (21) · Neuromuscular Diseases (19) · Peripheral Nervous System Diseases (19) · Nervous System Neoplasms (18) · Peripheral Nervous System Neoplasms (18) · Neoplasms, Connective Tissue (11) · Neoplasms, Connective and Soft Tissue (11) · Neoplasms, Fibrous Tissue (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10)
Doxorubicin (8) · Ifosfamide (7) · Radiotherapy (5) · Filgrastim (2) · AZD 6244 (1) · Acceptance and Commitment Therapy (1) · Carboplatin (1) · Chemotherapy, Adjuvant (1) · Cholecalciferol (1) · Combined Modality Therapy (1) · Control Groups (1) · Diathermy (1) · Etoposide (1) · HDAC-42 (1) · Imatinib Mesylate (1)
European Organisation for Research and Treatment of Cancer - EORTC (6) · National Cancer Institute (NCI) (3) · Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Beijing Tiantan Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Children's Oncology Group (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Erasmus Medical Center (1) · Medical University of Vienna (1) · Newron Pharmaceuticals SPA (1) · Nobelpharma (1) · Ramathibodi Hospital (1)
United States (10) · United Kingdom (8) · Canada (7) · France (7) · Germany (7) · Spain (6) · Belgium (5) · Netherlands (5) · Austria (4) · China (4) · Denmark (4) · Puerto Rico (4) · Slovakia (4) · Poland (3) · Switzerland (3)
A.N. Van Geel, MD (1) · Aaron R Weiss (1) · Alice P. Chen, MD (1) · Henriette A Moll, MD, PhD (1) · Ian R. Judson, MA, MD, FRCP (1) · James E. Butrynski, MD (1) · Jason R Fangusaro (1) · Laurence H. Baker, DO, FACOI (1) · Martin Robinson, MD (1) · Nguyen Binh Bui, MD (1) · Paul C. Lorigan, MD (1) · Penella J. Woll, MD, PhD (1)
PMID 17634494, PMID 20434400, PMID 22954508, PMID 24618336, PMID 24747207, PMID 28391003, PMID 29450452, PMID 30954717, PMID 31786124, PMID 32702309, PMID 32827353, PMID 33395032, PMID 33548339, PMID 34515544, PMID 34623899, PMID 34666214, PMID 36566574, PMID 37523624, PMID 38757485, PMID 39122389, PMID 39340758, PMID 40121838, PMID 40473450, PMID 41386267, PMID 42035475
U10CA098543 (2), U10CA180886 (2), 2009 (1), 2018 (1), U10CA180830 (1)